메뉴 건너뛰기




Volumn 24, Issue 9, 2010, Pages

Metabolic syndrome after hormone-modifying therapy: Risks associated with antineoplastic therapy

Author keywords

[No Author keywords available]

Indexed keywords

AFINITOR; AROMATASE INHIBITOR; BEVACIZUMAB; BLEOMYCIN; CISPLATIN; ETOPOSIDE; EVEROLIMUS; IMATINIB; SUNITINIB; TAMOXIFEN; TEMSIROLIMUS; UNCLASSIFIED DRUG; VINBLASTINE;

EID: 77958034196     PISSN: 08909091     EISSN: 08909091     Source Type: Journal    
DOI: None     Document Type: Review
Times cited : (9)

References (59)
  • 1
    • 79958237659 scopus 로고    scopus 로고
    • Modelling the costs of care of hypertension in patients with metabolic syndrome and its consequences, in Germany, Spain and Italy
    • Apr 20 Epub ahead of print. DOI 10.1007/s10198-010-0223-9
    • Wille E, Scholze J, Alegria E, et al: Modelling the costs of care of hypertension in patients with metabolic syndrome and its consequences, in Germany, Spain and Italy. Eur J Health Econ Apr 20 2010. [Epub ahead of print.] DOI 10.1007/s10198-010-0223-9.
    • (2010) Eur J Health Econ
    • Wille, E.1    Scholze, J.2    Alegria, E.3
  • 2
    • 0037463608 scopus 로고    scopus 로고
    • The metabolic syndrome: Prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994
    • Park YW, Zhu S, Palaniappan L, et al: The metabolic syndrome: Prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 163:427-436, 2003.
    • (2003) Arch Intern Med , vol.163 , pp. 427-436
    • Park, Y.W.1    Zhu, S.2    Palaniappan, L.3
  • 3
    • 0037116641 scopus 로고    scopus 로고
    • Prevalence of the metabolic syndrome among US adults: Findings from the Third National Health and Nutrition Examination Survey
    • Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults: Findings from the Third National Health and Nutrition Examination Survey. JAMA 287:356-359, 2002. (Pubitemid 34251969)
    • (2002) Journal of the American Medical Association , vol.287 , Issue.3 , pp. 356-359
    • Ford, E.S.1    Giles, W.H.2    Dietz, W.H.3
  • 5
    • 58149265222 scopus 로고    scopus 로고
    • Long-term rates of cardiovascular events in patients with the metabolic syndrome according to severity of coronary-angiographic alterations
    • Solymoss BC, Bourassa MG, Marcil M, et al: Long-term rates of cardiovascular events in patients with the metabolic syndrome according to severity of coronary-angiographic alterations. Coron Artery Dis 20:1-8, 2009.
    • (2009) Coron Artery Dis , vol.20 , pp. 1-8
    • Solymoss, B.C.1    Bourassa, M.G.2    Marcil, M.3
  • 6
    • 54049091645 scopus 로고    scopus 로고
    • Nonalcoholic fatty liver disease: Hepatic manifestation of obesity and the metabolic syndrome
    • Boppidi H, Daram SR: Nonalcoholic fatty liver disease: Hepatic manifestation of obesity and the metabolic syndrome. Postgrad Med 120:E01-E07, 2008.
    • (2008) Postgrad Med , vol.120
    • Boppidi, H.1    Daram, S.R.2
  • 7
    • 77949653961 scopus 로고    scopus 로고
    • Fatty liver disease in children: Eat now pay later
    • De Bruyne RM, Fitzpatrick E, Dhawan A: Fatty liver disease in children: Eat now pay later. Hepatol Int 4:375-385, 2010.
    • (2010) Hepatol Int , vol.4 , pp. 375-385
    • De Bruyne, R.M.1    Fitzpatrick, E.2    Dhawan, A.3
  • 8
    • 33749058933 scopus 로고    scopus 로고
    • Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer
    • Keating NL, OMalley AJ, Smith MR: Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24:4448-4456, 2006.
    • (2006) J Clin Oncol , vol.24 , pp. 4448-4456
    • Keating, N.L.1    OMalley, A.J.2    Smith, M.R.3
  • 9
    • 38049095554 scopus 로고    scopus 로고
    • Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trials
    • Cuppone F, Bria E, Verma S, et al: Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trials. Cancer 112:260-267, 2008.
    • (2008) Cancer , vol.112 , pp. 260-267
    • Cuppone, F.1    Bria, E.2    Verma, S.3
  • 10
    • 0015107440 scopus 로고
    • Metabolic studies in a patient with testicular feminization syndrome
    • Castaneda E, Perez AE, Guillen MA, et al: Metabolic studies in a patient with testicular feminization syndrome. Am J Obstet Gynecol 110:1002-1007, 1971.
    • (1971) Am J Obstet Gynecol , vol.110 , pp. 1002-1007
    • Castaneda, E.1    Perez, A.E.2    Guillen, M.A.3
  • 11
    • 0019943749 scopus 로고
    • Abnormalities of fuel metabolism in the polycystic ovary syndrome
    • Wortsman J, Soler NG: Abnormalities of fuel metabolism in the polycystic ovary syndrome. Obstet Gynecol 60:342-345, 1982.
    • (1982) Obstet Gynecol , vol.60 , pp. 342-345
    • Wortsman, J.1    Soler, N.G.2
  • 12
    • 43149087991 scopus 로고    scopus 로고
    • Body mass index and ovarian function are associated with endocrine and metabolic abnormalities in women with hyperandrogenic syndrome
    • DOI 10.1530/EJE-07-0515
    • Cupisti S, Kajaia N, Dittrich R, et al: Body mass index and ovarian function are associated with endocrine and metabolic abnormalities in women with hyperandrogenic syndrome. Eur J Endocrinol 158:711-719, 2008. (Pubitemid 351639610)
    • (2008) European Journal of Endocrinology , vol.158 , Issue.5 , pp. 711-719
    • Cupisti, S.1    Kajaia, N.2    Dittrich, R.3    Duezenli, H.4    Beckmann, M.W.5    Mueller, A.6
  • 13
    • 33644674139 scopus 로고    scopus 로고
    • Gender differences in the metabolic syndrome and their role for cardiovascular disease
    • Regitz-Zagrosek V, Lehmkuhl E, Weickert MO: Gender differences in the metabolic syndrome and their role for cardiovascular disease. Clin Res Cardiol 95:136-147, 2006.
    • (2006) Clin Res Cardiol , vol.95 , pp. 136-147
    • Regitz-Zagrosek, V.1    Lehmkuhl, E.2    Weickert, M.O.3
  • 14
    • 35048904131 scopus 로고    scopus 로고
    • Duration of testosterone suppression and the risk of death from prostate cancer in men treated using radiation and 6 months of hormone therapy
    • DAmico AV, Renshaw AA, Loffredo B, Chen MH: Duration of testosterone suppression and the risk of death from prostate cancer in men treated using radiation and 6 months of hormone therapy. Cancer 110:1723-1728, 2007.
    • (2007) Cancer , vol.110 , pp. 1723-1728
    • DAmico, A.V.1    Renshaw, A.A.2    Loffredo, B.3    Chen, M.H.4
  • 15
    • 27744507677 scopus 로고    scopus 로고
    • Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: Results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial
    • Denham JW, Steigler A, Lamb DS, et al: Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: Results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 6:841-850, 2005.
    • (2005) Lancet Oncol , vol.6 , pp. 841-850
    • Denham, J.W.1    Steigler, A.2    Lamb, D.S.3
  • 17
    • 34648828214 scopus 로고    scopus 로고
    • Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer
    • Saigal CS, Gore JL, Krupski TL, et al: Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 110:1493-1500, 2007.
    • (2007) Cancer , vol.110 , pp. 1493-1500
    • Saigal, C.S.1    Gore, J.L.2    Krupski, T.L.3
  • 19
    • 68149138117 scopus 로고    scopus 로고
    • The dark side of testosterone deficiency: III. Cardiovascular disease
    • Traish AM, Saad F, Feeley RJ, Guay AT: The dark side of testosterone deficiency: III. Cardiovascular disease. J Androl 30:477-494, 2009.
    • (2009) J Androl , vol.30 , pp. 477-494
    • Traish, A.M.1    Saad, F.2    Feeley, R.J.3    Guay, A.T.4
  • 20
    • 37349025015 scopus 로고    scopus 로고
    • Association between androgen-deprivation therapy and incidence of diabetes among males with prostate cancer
    • Lage MJ, Barber BL, Markus RA: Association between androgen-deprivation therapy and incidence of diabetes among males with prostate cancer. Urology 70:1104-1108, 2007.
    • (2007) Urology , vol.70 , pp. 1104-1108
    • Lage, M.J.1    Barber, B.L.2    Markus, R.A.3
  • 21
    • 31544440178 scopus 로고    scopus 로고
    • Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy
    • Basaria S, Muller DC, Carducci MA, et al: Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer 106:581-588, 2006.
    • (2006) Cancer , vol.106 , pp. 581-588
    • Basaria, S.1    Muller, D.C.2    Carducci, M.A.3
  • 22
    • 58149310816 scopus 로고    scopus 로고
    • The dark side of testosterone deficiency: II. Type 2 diabetes and insulin resistance
    • Traish AM, Saad F, Guay A: The dark side of testosterone deficiency: II. Type 2 diabetes and insulin resistance. J Androl 30:23-32, 2009.
    • (2009) J Androl , vol.30 , pp. 23-32
    • Traish, A.M.1    Saad, F.2    Guay, A.3
  • 23
    • 39549097295 scopus 로고    scopus 로고
    • Adipocytokines, Obesity, and Insulin Resistance during Combined Androgen Blockade for Prostate Cancer
    • DOI 10.1016/j.urology.2007.08.035, PII S0090429507020353
    • Smith MR, Lee H, Fallon MA, Nathan DM: Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer. Urology 71:318-322, 2008. (Pubitemid 351282338)
    • (2008) Urology , vol.71 , Issue.2 , pp. 318-322
    • Smith, M.R.1    Lee, H.2    Fallon, M.A.3    Nathan, D.M.4
  • 24
    • 35148842094 scopus 로고    scopus 로고
    • Risk of new-onset diabetes mellitus and worsening glycaemic variables for established diabetes in men undergoing androgen-deprivation therapy for prostate cancer
    • Derweesh IH, Diblasio CJ, Kincade MC, et al: Risk of new-onset diabetes mellitus and worsening glycaemic variables for established diabetes in men undergoing androgen-deprivation therapy for prostate cancer. BJU Int 100:1060-1065, 2007.
    • (2007) BJU Int , vol.100 , pp. 1060-1065
    • Derweesh, I.H.1    Diblasio, C.J.2    Kincade, M.C.3
  • 26
    • 0025931791 scopus 로고
    • Effects of tamoxifen on cardiovascular risk factors in postmenopausal women
    • Love RR, Wiebe DA, Newcomb PA, et al: Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Intern Med 115:860-864, 1991.
    • (1991) Ann Intern Med , vol.115 , pp. 860-864
    • Love, R.R.1    Wiebe, D.A.2    Newcomb, P.A.3
  • 27
    • 0026764412 scopus 로고
    • Long term effects of tamoxifen on blood lipid values in breast cancer
    • Dewar JA, Horobin JM, Preece PE, et al: Long term effects of tamoxifen on blood lipid values in breast cancer. BMJ 305:225-226, 1992.
    • (1992) BMJ , vol.305 , pp. 225-226
    • Dewar, J.A.1    Horobin, J.M.2    Preece, P.E.3
  • 28
    • 0029848389 scopus 로고    scopus 로고
    • Effects of chemotherapy-induced castration on serum lipids and apoproteins in premenopausal women with node-positive breast cancer
    • DOI 10.1210/jc.81.12.4453
    • Saarto T, Blomqvist C, Ehnholm C, et al: Effects of chemotherapy-induced castration on serum lipids and apoproteins in premenopausal women with node-positive breast cancer. J Clin Endocrinol Metab 81:4453-4457, 1996. (Pubitemid 26412060)
    • (1996) Journal of Clinical Endocrinology and Metabolism , vol.81 , Issue.12 , pp. 4453-4457
    • Saarto, T.1    Blomqvist, C.2    Ehnholm, C.3    Taskinen, M.-R.4    Elomaa, I.5
  • 29
    • 0029096747 scopus 로고
    • Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. The Scottish Cancer Trials Breast Group
    • McDonald CC, Alexander FE, Whyte BW, et al: Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. The Scottish Cancer Trials Breast Group. BMJ 311:977-980, 1995.
    • (1995) BMJ , vol.311 , pp. 977-980
    • McDonald, C.C.1    Alexander, F.E.2    Whyte, B.W.3
  • 30
    • 19344364880 scopus 로고    scopus 로고
    • Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials
    • Early Breast Cancer Trialists Collaborative Group (EBCTCG)
    • Early Breast Cancer Trialists Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005.
    • (2005) Lancet , vol.365 , pp. 1687-1717
  • 31
    • 33746408229 scopus 로고    scopus 로고
    • Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: Long-term safety analysis of the ATAC trial
    • Arimidex, Tamoxifen, Alone or in Combination Trialists Group
    • Arimidex, Tamoxifen, Alone or in Combination Trialists Group, Buzdar A, Howell A, et al: Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: Long-term safety analysis of the ATAC trial. Lancet Oncol 7:633-643, 2006.
    • (2006) Lancet Oncol , vol.7 , pp. 633-643
    • Buzdar, A.1    Howell, A.2
  • 33
    • 37649008623 scopus 로고    scopus 로고
    • Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: Safety analysis of BIG 1-98 trial
    • Mouridsen H, Keshaviah A, Coates AS, et al: Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: Safety analysis of BIG 1-98 trial. J Clin Oncol 25:5715-5722, 2007.
    • (2007) J Clin Oncol , vol.25 , pp. 5715-5722
    • Mouridsen, H.1    Keshaviah, A.2    Coates, A.S.3
  • 34
    • 29544433211 scopus 로고    scopus 로고
    • A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer
    • Thurlimann B, Keshaviah A, Coates AS, et al: A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353:2747-2757, 2005.
    • (2005) N Engl J Med , vol.353 , pp. 2747-2757
    • Thurlimann, B.1    Keshaviah, A.2    Coates, A.S.3
  • 35
    • 33749121807 scopus 로고    scopus 로고
    • Ezetimibe: Effective and safe treatment for dyslipidaemia associated with nonalcoholic fatty liver disease
    • Response to: Toth PP, Davidson MH: Simvastatin and ezetimibe: Combination therapy for the management of dyslipidaemia. Expert Opin Pharmacother 6:131-139, 2005
    • Ahmed MH, Saad RA, Osman MM: Ezetimibe: Effective and safe treatment for dyslipidaemia associated with nonalcoholic fatty liver disease. Response to: Toth PP, Davidson MH: Simvastatin and ezetimibe: Combination therapy for the management of dyslipidaemia. Expert Opin Pharmacother 6:131-139, 2005. Expert Opin Drug Saf 5:487-488, 2006.
    • (2006) Expert Opin Drug Saf , vol.5 , pp. 487-488
    • Ahmed, M.H.1    Saad, R.A.2    Osman, M.M.3
  • 36
    • 0035131855 scopus 로고    scopus 로고
    • Relationships between tamoxifen use, liver fat and body fat distribution in women with breast cancer
    • DOI 10.1038/sj.ijo.0801488
    • Nguyen MC, Stewart RB, Banerji MA, et al: Relationships between tamoxifen use, liver fat and body fat distribution in women with breast cancer. Int J Obes Relat Metab Disord 25:296-298, 2001. (Pubitemid 33593532)
    • (2001) International Journal of Obesity , vol.25 , Issue.SUPPL. 2 , pp. 296-298
    • Nguyen, M.C.1    Stewart, R.B.2    Banerji, M.A.3    Gordon, D.H.4    Kral, J.G.5
  • 37
    • 20244370881 scopus 로고    scopus 로고
    • Incidence and risk factors for non-alcoholic steatohepatitis: Prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial
    • Bruno S, Maisonneuve P, Castellana P, et al: Incidence and risk factors for non-alcoholic steatohepatitis: Prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial. BMJ 330:932, 2005.
    • (2005) BMJ , vol.330 , pp. 932
    • Bruno, S.1    Maisonneuve, P.2    Castellana, P.3
  • 38
    • 44649178193 scopus 로고    scopus 로고
    • Bilateral oophorectomy before 50 years of age is significantly associated with the metabolic syndrome and Framingham risk score: A controlled, population-based study (HUNT-2)
    • Dørum A, Tonstad S, Liavaag AH, et al: Bilateral oophorectomy before 50 years of age is significantly associated with the metabolic syndrome and Framingham risk score: A controlled, population-based study (HUNT-2). Gynecol Oncol 109:377-383, 2008.
    • (2008) Gynecol Oncol , vol.109 , pp. 377-383
    • Dørum, A.1    Tonstad, S.2    Liavaag, A.H.3
  • 39
    • 57649178821 scopus 로고    scopus 로고
    • Metabolic syndrome after risk-reducing salpingo-oophorectomy in women at high risk for hereditary breast ovarian cancer: A controlled observational study
    • Michelsen TM, Pripp AH, Tonstad S, et al: Metabolic syndrome after risk-reducing salpingo-oophorectomy in women at high risk for hereditary breast ovarian cancer: A controlled observational study. Eur J Cancer 45:82-89, 2009.
    • (2009) Eur J Cancer , vol.45 , pp. 82-89
    • Michelsen, T.M.1    Pripp, A.H.2    Tonstad, S.3
  • 40
    • 0003964363 scopus 로고    scopus 로고
    • Available at Accessed July 16, 2010
    • American Cancer Society: Cancer facts & figures 2010. Available at http://www.cancer.org/acs/groups/content/@nho/ documents/document/acspc-024113. pdf. Accessed July 16, 2010.
    • Cancer Facts & Figures 2010
  • 43
    • 24644519960 scopus 로고    scopus 로고
    • Blood pressure and body mass index in long-term survivors of testicular cancer
    • Sagstuen H, Aass N, Fossa SD, et al: Blood pressure and body mass index in long-term survivors of testicular cancer. J Clin Oncol 23:4980-4990, 2005.
    • (2005) J Clin Oncol , vol.23 , pp. 4980-4990
    • Sagstuen, H.1    Aass, N.2    Fossa, S.D.3
  • 44
    • 17644431109 scopus 로고    scopus 로고
    • Cardiovascular morbidity in long-term survivors of metastatic testicular cancer
    • Meinardi MT, Gietema JA, van der Graaf WT, et al: Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol 18:1725-1732, 2000.
    • (2000) J Clin Oncol , vol.18 , pp. 1725-1732
    • Meinardi, M.T.1    Gietema, J.A.2    Van Der Graaf, W.T.3
  • 45
    • 52249116769 scopus 로고    scopus 로고
    • Predicted cardiovascular mortality and reported cardiovascular morbidity in testicular cancer survivors
    • Haugnes HS, Aass N, Fossa SD, et al: Predicted cardiovascular mortality and reported cardiovascular morbidity in testicular cancer survivors. J Cancer Surviv 2:128-137, 2008.
    • (2008) J Cancer Surviv , vol.2 , pp. 128-137
    • Haugnes, H.S.1    Aass, N.2    Fossa, S.D.3
  • 46
    • 33644835617 scopus 로고    scopus 로고
    • Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer
    • van den Belt-Dusebout AW, Nuver J, de Wit R, et al: Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 24:467-475, 2006.
    • (2006) J Clin Oncol , vol.24 , pp. 467-475
    • Van Den Belt-Dusebout, A.W.1    Nuver, J.2    De Wit, R.3
  • 47
    • 0027082709 scopus 로고
    • Hypercholesterolemia after chemotherapy for testis cancer
    • Raghavan D, Cox K, Childs A, et al: Hypercholesterolemia after chemotherapy for testis cancer. J Clin Oncol 10:1386-1389, 1992.
    • (1992) J Clin Oncol , vol.10 , pp. 1386-1389
    • Raghavan, D.1    Cox, K.2    Childs, A.3
  • 48
    • 0037434420 scopus 로고    scopus 로고
    • Excessive annual BMI increase after chemotherapy among young survivors of testicular cancer
    • DOI 10.1038/sj.bjc.6600714
    • Nord C, Fossa SD, Egeland T: Excessive annual BMI increase after chemotherapy among young survivors of testicular cancer. Br J Cancer 88:36-41, 2003. (Pubitemid 36241215)
    • (2003) British Journal of Cancer , vol.88 , Issue.1 , pp. 36-41
    • Nord, C.1    Fossa, S.D.2    Egeland, T.3
  • 50
    • 33746637660 scopus 로고    scopus 로고
    • Current development of mTOR inhibitors as anticancer agents
    • Faivre S, Kroemer G, Raymond E: Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 5:671-688, 2006.
    • (2006) Nat Rev Drug Discov , vol.5 , pp. 671-688
    • Faivre, S.1    Kroemer, G.2    Raymond, E.3
  • 51
    • 77951282223 scopus 로고    scopus 로고
    • Emergent toxicities associated with the use of mTOR inhibitors in patients with advanced renal carcinoma
    • Rodriguez-Pascual J, Cheng E, Maroto P, Duran I: Emergent toxicities associated with the use of mTOR inhibitors in patients with advanced renal carcinoma. Anticancer Drugs 21:478-486, 2010.
    • (2010) Anticancer Drugs , vol.21 , pp. 478-486
    • Rodriguez-Pascual, J.1    Cheng, E.2    Maroto, P.3    Duran, I.4
  • 52
    • 77951729433 scopus 로고    scopus 로고
    • FDA approval summary: Temsirolimus as treatment for advanced renal cell carcinoma
    • Kwitkowski VE, Prowell TM, Ibrahim A,: FDA approval summary: Temsirolimus as treatment for advanced renal cell carcinoma. Oncologist 15:428-435, 2010.
    • (2010) Oncologist , vol.15 , pp. 428-435
    • Kwitkowski, V.E.1    Prowell, T.M.2    Ibrahim, A.3
  • 53
    • 48749128305 scopus 로고    scopus 로고
    • Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features
    • Bellmunt J, Szczylik C, Feingold J, et al: Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Ann Oncol 19:1387-1392, 2008.
    • (2008) Ann Oncol , vol.19 , pp. 1387-1392
    • Bellmunt, J.1    Szczylik, C.2    Feingold, J.3
  • 54
    • 48649107474 scopus 로고    scopus 로고
    • Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial
    • Motzer RJ, Escudier B, Oudard S, et al: Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial. Lancet 372:449-456, 2008.
    • (2008) Lancet , vol.372 , pp. 449-456
    • Motzer, R.J.1    Escudier, B.2    Oudard, S.3
  • 55
    • 33644847440 scopus 로고    scopus 로고
    • Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer
    • Faivre S, Delbaldo C, Vera K, et al: Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24:25-35, 2006.
    • (2006) J Clin Oncol , vol.24 , pp. 25-35
    • Faivre, S.1    Delbaldo, C.2    Vera, K.3
  • 56
    • 23044510046 scopus 로고    scopus 로고
    • Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors
    • Clark JW, Eder JP, Ryan D, et al: Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res 11:5472-5480, 2005.
    • (2005) Clin Cancer Res , vol.11 , pp. 5472-5480
    • Clark, J.W.1    Eder, J.P.2    Ryan, D.3
  • 57
    • 74549205409 scopus 로고    scopus 로고
    • Management of sorafenib, sunitinib, and temsirolimus toxicity in metastatic renal cell carcinoma
    • Guevremont C, Alasker A, Karakiewicz PI: Management of sorafenib, sunitinib, and temsirolimus toxicity in metastatic renal cell carcinoma. Curr Opin Support Palliat Care 3:170-179, 2009.
    • (2009) Curr Opin Support Palliat Care , vol.3 , pp. 170-179
    • Guevremont, C.1    Alasker, A.2    Karakiewicz, P.I.3
  • 58
    • 0037208589 scopus 로고    scopus 로고
    • Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer
    • Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al: Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21:60-65, 2003.
    • (2003) J Clin Oncol , vol.21 , pp. 60-65
    • Kabbinavar, F.1    Hurwitz, H.I.2    Fehrenbacher, L.3
  • 59
    • 34248339065 scopus 로고    scopus 로고
    • Short- vs long-term androgen suppression plus external beam radiation therapy and survival in men of advanced age with node-negative high-risk adenocarcinoma of the prostate
    • DAmico AV, Denham JW, Bolla M, et al: Short- vs long-term androgen suppression plus external beam radiation therapy and survival in men of advanced age with node-negative high-risk adenocarcinoma of the prostate. Cancer 109:2004-2010, 2007.
    • (2007) Cancer , vol.109 , pp. 2004-2010
    • DAmico, A.V.1    Denham, J.W.2    Bolla, M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.